Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

Adoptive cellular therapy using chimeric antigen receptor (CAR) T cell therapies have produced significant objective responses in patients with CD19(+) hematological malignancies, including durable complete responses. Although the majority of clinical trials to date have used autologous patient cell...

Descripción completa

Detalles Bibliográficos
Autores principales: MacLeod, Daniel T., Antony, Jeyaraj, Martin, Aaron J., Moser, Rachel J., Hekele, Armin, Wetzel, Keith J., Brown, Audrey E., Triggiano, Melissa A., Hux, Jo Ann, Pham, Christina D., Bartsevich, Victor V., Turner, Caitlin A., Lape, Janel, Kirkland, Samantha, Beard, Clayton W., Smith, Jeff, Hirsch, Matthew L., Nicholson, Michael G., Jantz, Derek, McCreedy, Bruce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383629/
https://www.ncbi.nlm.nih.gov/pubmed/28237835
http://dx.doi.org/10.1016/j.ymthe.2017.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383629/
https://www.ncbi.nlm.nih.gov/pubmed/28237835
http://dx.doi.org/10.1016/j.ymthe.2017.02.005

Ejemplares similares